Finally, a rare number of sq-BLCA samples were characterized by both ARID1A protein loss and strong PD-L1 expression suggesting a putative benefit upon immune checkpoint inhibitor therapy. This evidence concerns the gene ARID1A and bladder transitional cell carcinoma.